Eurosurv. SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020

[tetano]

• SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020
• Sheila F Lumley^1,2,3 , David W Eyre^1,2,3,4 , Anna L McNaughton^1,3 , Alison Howarth⁵ , Sarah Hoosdally⁵ , Stephanie B Hatch⁶ , James Kavanagh⁵ , Kevin K Chau⁵ , Louise O Downs² , Stuart Cox⁷ , Laura Dunn² , Anita Justice² , Susan Wareing² , Kate Dingle⁵ , Justine Rudkin⁴ , Kathryn Auckland⁵ , Alexander Fyfe⁸ , Jai Bolton⁸ , Robert Paton⁸ , Alexander J Mentzer^2,5 , Katie Jeffery² , Monique I Andersson² , Tim James⁷ , Tim E A Peto^2,5 , Brian D Marsden^9,10,11 , Gavin Screaton¹² , Richard J Cornall¹² , Paul Klenerman^1,2,5 , Daniel Ebner⁶ , David I Stuart^6,10,11 , Derrick W Crook^2,5 , Nicole Stoesser^2,5 , Stephen H Kennedy¹³ , Craig Thompson⁸ , Sunetra Gupta⁸ , Philippa C Matthews^1,2,3,5

During the first peak of the coronavirus disease (COVID-19) pandemic in the United Kingdom (UK) between April and June 2020, we set out to generate a benchmark estimate of antenatal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in a population of pregnant women in the Oxford area. We also evaluated an IgG enzyme-linked immunosorbent assay (ELISA) head-to-head with a pseudotyped virus neutralisation test in this group, and investigated the extent to which routine antenatal testing for SARS-CoV-2 IgG antibody could inform population surveillance efforts.

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.41.2001721#html_fulltext